Claims for Patent: 12,447,156

Summary for Patent: 12,447,156

Title:	Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors
Abstract:	Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing mean pruritus score, mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.
Inventor(s):	Per-Göran Gillberg, Jan Mattsson, Pat HORN, Paresh Soni
Assignee:	Albireo AB
Application Number:	US18/098,755
Patent Claims:	1. A method for treating pruritus associated with progressive familial intrahepatic cholestasis (PFIC) in a subject in need thereof, the method comprising orally administering to the subject a therapeutically effective amount of a pharmaceutical formulation comprising odevixibat, or a pharmaceutically acceptable salt thereof, wherein following administration of the pharmaceutical formulation, the subject exhibits a reduction in pruritus score, and wherein the pharmaceutical formulation comprising odevixibat, or a pharmaceutically acceptable salt thereof, comprises a plurality of particles, wherein each particle comprises odevixibat, or a pharmaceutically acceptable salt thereof, and each particle of the formulation substantially contains the same amount of odevixibat. 2. The method of claim 1, wherein the subject is administered from about 40 μg/kg/day to about 120 μg/kg/day of odevixibat, or a pharmaceutically acceptable salt thereof. 3. The method of claim 1, wherein the subject is administered 40 μg/kg/day of odevixibat, or a pharmaceutically acceptable salt thereof. 4. The method of claim 3, wherein the subject is administered 40 μg/kg/day of odevixibat, or a pharmaceutically acceptable salt thereof, in the morning and with food. 5. The method of claim 1, wherein the subject is administered 120 μg/kg/day of odevixibat, or a pharmaceutically acceptable salt thereof. 6. The method of claim 1, wherein the method comprises administering 200 μg, 400 μg, 600 μg, or 1200 μg of odevixibat, or a pharmaceutically acceptable salt thereof, to the subject. 7. The method of claim 1, wherein each particle comprises odevixibat, or a pharmaceutically acceptable salt thereof, in an amount of from about 0.1% w/w to about 5.0% w/w based on the total weight of the particle. 8. The method of claim 7, wherein each particle comprises a core and a coating layer surrounding the core. 9. The method of claim 8, wherein the core comprises microcrystalline cellulose. 10. The method of claim 8, wherein the coating layer comprises odevixibat, or a pharmaceutically acceptable salt thereof. 11. The method of claim 10, wherein the coating layer does not contain odevixibat agglomerates having a d90 particle size distribution of greater than 15 m. 12. The method of claim 7, wherein the odevixibat is present as a hydrate of odevixibat. 13. The method of claim 12, wherein the odevixibat is present as a sesquihydrate. 14. The method of claim 1, wherein the plurality of particles are contained within a capsule. 15. The method of claim 14, wherein each particle comprises odevixibat, or a pharmaceutically acceptable salt thereof, in an amount of from about 0.1% w/w to about 5.0% w/w based on the total weight of the particle. 16. The method of claim 15, wherein the capsule contains from about 20 to about 100 mg of the particles. 17. The method of claim 14, wherein the capsule contains 200 μg, 400 μg, 600 μg, or 1200 μg of odevixibat, or a pharmaceutically acceptable salt thereof. 18. The method of claim 14, wherein the odevixibat is present as a hydrate of odevixibat. 19. The method of claim 18, wherein the odevixibat is present as a sesquihydrate. 20. The method of claim 14, wherein each particle comprises: a) a core, wherein the core comprises microcrystalline cellulose, and b) a coating layer surrounding the core, wherein the coating layer comprises hypromellose and odevixibat present as a sesquihydrate. 21. The method of claim 1, wherein the reduction in pruritus score is at least 0.5, at least 0.6, at least 0.7, at least 0.8, at least 0.9, at least 1.0, at least 1.1, at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1.8, at least 1.9, or at least 2.0. 22. The method of claim 21, wherein the reduction in pruritus score is compared to a baseline score using an observer-reported outcome instrument. 23. The method of claim 1, wherein the reduction in pruritus score occurs following daily administration of the pharmaceutical formulation for at least 4 weeks, at least 8 weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, or at least 24 weeks. 24. The method of claim 1, wherein the PFIC is selected from: PFIC 1, PFIC 2, PFIC 3, or PFIC 6. 25. The method of claim 1, wherein the subject is a pediatric subject.